Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.

Jackson DO, Trappey FA, Clifton GT, Vreeland TJ, Peace KM, Hale DF, Litton JK, Murray JL, Perez SA, Papamichail M, Mittendorf EA, Peoples GE.

Clin Immunol. 2018 Jul 17;195:28-35. doi: 10.1016/j.clim.2018.06.008. [Epub ahead of print]

PMID:
30025819
2.

Resection of a Perirectal Leiomyosarcoma via a Posterior Transcoccygeal Approach.

Asare EA, Vreeland TJ, Feig BW.

Ann Surg Oncol. 2018 Sep;25(9):2641. doi: 10.1245/s10434-018-6636-x. Epub 2018 Jul 6.

PMID:
29981026
3.

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.

Herbert GS, Vreeland TJ, Clifton GT, Greene JM, Jackson DO, Hardin MO, Hale DF, Berry JS, Nichol P, Yin S, Yu X, Wagner TE, Peoples GE.

Vaccine. 2018 May 31;36(23):3247-3253. doi: 10.1016/j.vaccine.2018.04.078. Epub 2018 May 1.

PMID:
29724512
4.

Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.

Vreeland TJ, Litton JK, Qiao N, Philips AV, Alatrash G, Hale DF, Jackson DO, Peace KM, Greene JM, Berry JS, Clifton GT, Peoples GE, Mittendorf EA.

Clin Immunol. 2018 Jul;192:6-13. doi: 10.1016/j.clim.2018.03.010. Epub 2018 Mar 21.

PMID:
29574039
5.

Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.

Hardin MO, Vreeland TJ, Clifton GT, Hale DF, Herbert GS, Greene JM, Jackson DO, Berry JE, Nichols P, Yin S, Yu X, Wagner TE, Peoples GE.

Immunotherapy. 2018 Apr;10(5):373-382. doi: 10.2217/imt-2017-0114.

PMID:
29473470
6.

Timing of Pancreatic Resection and Patient Outcomes: Is There a Difference?

Vreeland TJ, Katz MHG.

Surg Clin North Am. 2018 Feb;98(1):57-71. doi: 10.1016/j.suc.2017.09.006. Review.

PMID:
29191278
7.

Routine Pre-Treatment MRI for Breast Cancer in a Single-Payer Medical Center: Effects on Surgical Choices, Timing and Outcomes.

Vreeland TJ, Berry Iv JS, Schneble E, Jackson DO, Herbert GS, Hale DF, Martin JM, Flores M, Pattyn AR, Hata K, Clifton GT, Kirkpatrick AD, Peoples GE.

J Cancer. 2017 Jul 23;8(13):2442-2448. doi: 10.7150/jca.16738. eCollection 2017.

8.

Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development.

Berry JS, Vreeland TJ, Hale DF, Jackson DO, Trappey AF, Greene JM, Hardin MO, Herbert GS, Clifton GT, Peoples GE.

J Cancer. 2017 May 11;8(7):1255-1262. doi: 10.7150/jca.16450. eCollection 2017.

9.

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.

Jackson DO, Byrd K, Vreeland TJ, Hale DF, Herbert GS, Greene JM, Schneble EJ, Berry JS, Trappey AF, Clifton GT, Hardin MO, Martin J, Elkas JC, Conrads TP, Darcy KM, Hamilton CA, Maxwell GL, Peoples GE.

Oncotarget. 2017 Feb 28;8(9):15912-15923. doi: 10.18632/oncotarget.13305.

10.

Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.

Vreeland TJ, Clifton GT, Herbert GS, Hale DF, Jackson DO, Berry JS, Peoples GE.

Expert Rev Clin Immunol. 2016 Dec;12(12):1347-1357. Epub 2016 Jun 28. Review.

PMID:
27323245
11.

Arming the Immune System Through Vaccination to Prevent Cancer Recurrence.

Hale DF, Vreeland TJ, Peoples GE.

Am Soc Clin Oncol Educ Book. 2016;35:e159-67. doi: 10.14694/EDBK_158946. Review.

12.

A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.

Greene JM, Schneble EJ, Jackson DO, Hale DF, Vreeland TJ, Flores M, Martin J, Herbert GS, Hardin MO, Yu X, Wagner TE, Peoples GE.

Cancer Immunol Immunother. 2016 Apr;65(4):383-92. doi: 10.1007/s00262-016-1809-6. Epub 2016 Feb 19.

PMID:
26894495
13.

Analysis of Clinical and Pathologic Factors of Pure, Flat Epithelial Atypia on Core Needle Biopsy to Aid in the Decision of Excision or Observation.

Berry JS, Trappey AF, Vreeland TJ, Pattyn AR, Clifton GT, Berry EA, Schneble EJ, Kirkpatrick AD, Saenger JS, Peoples GE.

J Cancer. 2016 Jan 1;7(1):1-6. doi: 10.7150/jca.12781. eCollection 2016.

14.

Cancer vaccines: should we be targeting patients with less aggressive disease?

Hale DF, Clifton GT, Sears AK, Vreeland TJ, Shumway N, Peoples GE, Mittendorf EA.

Expert Rev Vaccines. 2012 Jun;11(6):721-31. doi: 10.1586/erv.12.39. Review.

PMID:
22873128

Supplemental Content

Loading ...
Support Center